Caricamento...
Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer
SUMMARY: In women with estrogen receptor(ER)- and ErbB2 (HER2)-positive breast cancer, a vicious cycle is established between ER mechanisms of action and the growth factor receptor network, leading to enhanced cell proliferation and endocrine resistance. As such, co-targeting ErbB1 and ErbB2 with la...
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
S. Karger GmbH
2010
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2931095/ https://ncbi.nlm.nih.gov/pubmed/20847831 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000285775 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|